Organon & Co. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Organon is a global healthcare company focused on women’s health, biosimilars and established brands, with more than 60 products sold in over 140 countries and territories. It generated approximately 77% of 2022 revenue outside the United States. Organon became independent from Merck in June 2021, so historical comparisons include periods when it operated within Merck and reflect allocated costs and other separation-related differences.
Financial results and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $6.174 billion | $6.304 billion | Down 2% reported; up 4% excluding foreign exchange |
| Income from continuing operations | $917 million | $1.351 billion | Down 32% |
| Diluted EPS | $3.59 | $5.31 | Down 32% |
| Operating cash flow | $858 million | $2.160 billion | Down $1.302 billion |
| Capital expenditures | $196 million | $192 million | Up $4 million |
Calculated from reported figures, gross margin was approximately 62.8%, operating margin approximately 25.4%, and net margin approximately 14.8%. Operating cash flow less capital expenditures was approximately $662 million, versus $1.968 billion in 2021.
- Revenue mix: Women’s Health $1.673 billion (up from $1.612 billion); Biosimilars $481 million (up from $424 million); Established Brands $3.874 billion (down from $4.068 billion).
- Balance sheet at year-end: Cash and cash equivalents were $706 million; working capital was $1.4 billion. Total debt principal was approximately $8.9 billion, with $8.905 billion of long-term debt net of current portion. The $1 billion revolving credit facility had no borrowings outstanding; the company reported compliance with debt covenants.
- Interest and dividend: Interest expense was $422 million, versus $258 million in 2021. Organon paid $1.12 per share in 2022 and declared a $0.28 quarterly dividend in February 2023; future dividends remain at the Board’s discretion.
Material changes versus the prior year
- Reported worldwide sales declined 2%, primarily reflecting approximately $383 million of unfavorable foreign-exchange impact; sales increased 4% excluding currency effects. U.S. sales rose 4% and international sales declined 4% reported, but rose 4% excluding foreign exchange.
- Revenue growth excluding foreign exchange included Nexplanon, Renflexis, and certain respiratory and cardiovascular products. NuvaRing faced generic competition; established-brand declines included Zetia/Vytorin and Cozaar/Hyzaar.
- Income from continuing operations fell as interest expense rose and research and development spending increased 39% to $471 million. R&D growth reflected acquired clinical-stage assets, more clinical activity and employee-related costs.
- Operating cash flow fell substantially, primarily due to a decrease in trade payables, including balances with Merck. Working capital increased from $1.2 billion to $1.4 billion.
Outlook, management commentary and key risks
- Outlook: The filing provides no quantitative 2023 revenue or earnings guidance. Organon expected to launch Xaciato in the United States in the first half of 2023, and Hadlima in the United States in June 2023. It anticipated continued NuvaRing declines from generic competition and further effects from China’s volume-based procurement program.
- Business development: 2022 agreements expanded the pipeline and product rights, including licensing arrangements with Henlius, Cirqle and Daré, and the acquisition of Marvelon/Mercilon rights in China and Vietnam. Potential contractual milestone payments totaled $2.4 billion, of which $38 million was due within the next 12 months; payments depend on achieving specified milestones. Purchase obligations totaled $1.2 billion, including $343 million due within 12 months.
- COVID-19 and China: Organon reported approximately $46 million of lower China product sales during 2022, primarily from lockdowns, clinic closures and reduced patient visits. Management noted ongoing uncertainty about pandemic-related effects.
- Supply and product quality: A Heist manufacturing inspection finding led to a $36 million inventory charge affecting selected injectable steroid brands. Organon also reported market actions, including recalls in certain markets, for Diprospan and certain Celestone injections related to a non-conforming manufacturing-line component; management said it did not expect a material impact. The filing identifies sole-source materials and reliance on external suppliers as supply risks.
- Pricing, competition and exclusivity: Key risks include generic and biosimilar competition, loss of exclusivity, government pricing and reimbursement controls, and U.S. drug-pricing reforms. China VBP reduced sales by approximately $20 million year over year; loss of exclusivity reduced sales by approximately $30 million, mainly affecting NuvaRing.
- Other risks and contingencies: Organon had substantial indebtedness and debt covenants that can constrain financing, dividends and strategic actions. The filing describes product-liability, patent and governmental matters, including Merck litigation for which Organon may have indemnification obligations. The company reported no clear estimate of possible losses for certain litigation matters. Environmental liabilities accrued were $20 million; estimated remediation spending for 2023–2027 was $16 million.
- Unusual item: Organon recorded a fourth-quarter 2022 out-of-period adjustment for pre-separation employee expenses. The correction increased 2022 net income by approximately $19 million and corrected an approximately $19 million understatement of 2021 net income; the company concluded it was not material to either period.
- Controls and audit: Management and PwC concluded internal control over financial reporting was effective as of December 31, 2022. PwC identified U.S. Medicaid and managed-care rebate accruals as a critical audit matter because estimating them involves significant judgment and measurement uncertainty.
Important facts for investors to verify
- Whether revenue growth excluding foreign exchange can continue and how currency movements, China VBP and generic competition affect reported sales and margins.
- Cash conversion and debt-servicing capacity, given the decline in operating cash flow, $8.9 billion of debt and rising interest expense.
- Progress, regulatory outcomes and commercial contribution from Hadlima, Xaciato, Jada and pipeline assets, alongside contingent milestone and royalty commitments.
- Any developments in the Heist manufacturing matter, product recalls, supply interruptions or sole-source supplier dependencies.
- Updates on litigation and indemnification exposure, particularly matters involving Fosamax, Nexplanon and Propecia/Proscar, and the adequacy of related reserves.
- The effects of the ERP implementation, remaining separation-related arrangements with Merck, and whether dividends remain supported by operating cash flow and debt covenants.